Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR)

NCT06898099 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-10-14
Last updated
2026-08-19

Condition(s) studied

Chronic Insomnia

Investigational drug(s) / intervention(s)

"Standard care" control group (without hypnosis)Experimental group: "E2R hypnosis"

"Standard care" control group (without hypnosis): Randomization stratification on insomnia severity. In the "Standard care" group, the investigating physician will not change his or her current practice as part of the study. Treatment will be the same as usual, whether drug-based or not (psychotherapy, etc.), with the exception of hypnosis. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study.

Experimental group: "E2R hypnosis": Randomization stratification on insomnia severity. For the patients randomized to the Hypnosis E2R arm, patients summoned within 15 days to 3 weeks of inclusion for their first hypnotherapy session with the hypnotherapist. All patients will receive 4 hypnotherapy sessions over 6 weeks using the E2R method. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Practice of self-hypnosis requested of the patient (patient diary), Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study.

Study summary

In France, the treatment of chronic insomnia relies mainly on hypnotic drugs in routine care, despite the high level of iatrogenicity. Cognitive-behavioral therapy (CBT) is recommended by the HAS as a non-pharmaceutical first-line therapy for chronic insomnia. Despite evidence of their efficacy in chronic insomnia, these therapies remain underdeveloped in France (few practitioners, time-consuming for the patient). Hypnotherapy is another non-drug intervention suitable for routine outpatient care. Among the hypnosis methods practiced in France, E2R (Emotion, Regression, Repair) is a hypnotherapy method used in general practice, particularly for chronic insomnia. To date, no clinical trials have been carried out to demonstrate its effectiveness in this pathology.

The HypERR study is a multicenter, randomized, open-label study designed to evaluate the efficacy of a hypotherapy method called E2R in the management of chronic insomnia, by comparing it with standard care (without hypnosis).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient aged 18 or over, * Patient suffering from chronic insomnia according to the DSM-5 definition, whether or not treated with psychotropic drugs: \* At least one of the following sleep disorders: difficulty in falling asleep, difficulty in maintaining sleep, waking up too early and inability to go back to sleep, and \* At least 3 nights a week for at least 3 months, and \* In an adequate night-time sleep context, and \* With at least one significant impact on, or impairment of, social, occupational or behavioral functioning, and \* Insomnia not attributable to the physiological effects of a substance, and \* Insomnia not explicable by a medical condition or mental disorder. * Patient willing to undergo hypnotherapy for 4 sessions of 30 min over 6 weeks, * Patient whose treating physician is the investigator, * Patient able to give free, informed, written consent, * Patient affiliated to the French social security system. Exclusion Criteria: * Patients receiving or having received one or more hypnotherapy sessions (for any reason) in the last 5 years prior to inclusion, * Patient participating in another study involving the treatment of insomnia or another pathology having an impact on sleep disorders, * Patient unable to complete a self-administered questionnaire, * Patients with poor or no understanding of the French language, * Patients unable to attend hypnotherapy consultations, * Deaf or hard-of-hearing patients without hearing aids, * Patient under legal protection (safeguard of justice, curatorship, guardianship) or deprived of liberty, * Women declaring themselves pregnant or breastfeeding.

Primary outcome measure(s)

  • Severity of Insomnia assessed by the Insomnia Severity Index (ISI) — 6 months
    Insomnia Severity Index (ISI). The minimum score is 0 meaning No Insomnia, the maximum is 28 meaning Severe clinical insomnia

Trial sites (35)

FacilityCityRegionStatus
Cabinet médical Bain-de-Bretagne France Recruiting
Cabinet médical de Plaisance Bouaye France Recruiting
Cabinet médical de Plaisance Bouaye France Recruiting
Cabinet médical de Breteil Breteil France Recruiting
Cabinet médical Cesson-Sévigné France Recruiting
Cabinet médical du Linon Combourg France Recruiting
Cabinet médical Sycamore Contres France Withdrawn
Cabinet médical de Corps Nuds Corps-Nuds France Not Yet Recruiting
Cabinet médical des Embruns Crac'h France Recruiting
Pôle Santé Physiomast Dol-de-Bretagne France Recruiting
MSP de l'Esplanade Guer France Recruiting
Maison médicale Iffendic France Recruiting
Cabinet Médical Chantepie Joué Les Tours France Recruiting
Cabinet Médical de Jugon-Les-Lacs -Saint-Igneuc Jugon-les-Lacs France Recruiting
Maison médicale des Longrais La Chapelle-des-Fougeretz France Recruiting
Cabinet médical La Chapelle-Saint-Ursin France Recruiting
Cabinet médical du Lion d'Or Nantes France Recruiting
Maison médicale Laennec Pleudihen-sur-Rance France Recruiting
Maison De Santé De Ronsouze Ploërmel France Recruiting
Cabinet médical Les Petits Ponts Pont-Saint-Martin France Recruiting
Cabinet médical Les Petits Ponts Pont-Saint-Martin France Recruiting
Maison de Santé de Questembert Questembert France Recruiting
Cabinet médical Olec Rennes France Recruiting
Cabinet médical Rennes France Recruiting
Maison médicale pluridisciplinaire Rouziers-de-Touraine France Recruiting
Maison médical de Maen roch Saint-Brice-en-Coglès France Recruiting
Maison médicale Saint-Gilles-Croix-de-Vie France Recruiting
Maison médicale Saint-Gilles-Croix-de-Vie France Recruiting
Maison de soin du Couesnon Saint-Ouen-des-Alleux France Recruiting
Cabinet médical Saint-Romain-sur-Cher France Recruiting
Maison de santé Sancerre France Recruiting
Cabinet médical de la Blanchisserie Sully-sur-Loire France Recruiting
Maison de santé Talensac France Recruiting
Cabinet des médecins généralistes de TIGY Tigy France Recruiting
Cabinet médical Vildé-Guingalan France Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06898099 on ClinicalTrials.gov ↗ ← All trials in France